ClinicalTrials.gg
Sign In
CompletedNCT07884578Updated Oct 21, 2026

The Effectiveness of Extracorporeal Shock Wave Therapy for Elbow Osteochondritis Dissecans (OCD)

An interventional study of Extracorporeal Shock Wave Therapy and Extracorporeal Shock Wave Therapy(no-energy) in Elbow Osteochondritis Dissecans, sponsored by Chang Gung Memorial Hospital. Completed at 1 site in Taiwan. Open to participants aged 15 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Chang Gung Memorial Hospital · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 6 years 7 months after the study started (first participant enrolled Feb 2020, registered Oct 2026).
Updated Oct 20, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
9
Allocation
Randomized
Ages
15 Years to 18 Years
Sex
All
01

Study summary

Extracorporeal shock wave therapy was performed on athletes aged 15-18 years with lateral maxillary chondritis of the elbow, and X-ray, blood tests, and MRI were conducted to evaluate the treatment progress.

Read the detailed description
  1. Phase 1: 52 patients were enrolled and randomly assigned to an experimental group and a control group. Under general anesthesia, the location of the osteochondritis dissociation in the humeral capitula was first located using fluoroscopy. Extracorporeal shock wave therapy (Storz) was then applied to the osteochondritis dissociation in the humeral capitula. The energy was randomly selected, with patients receiving 3000 impulses at 28kV. Postoperatively, the elbow joint was protected with a brace, and any weight-bearing movement or activity of the elbow joint was prohibited. The control group received Shame therapy, with the elbow joint protected with a brace, and any weight-bearing movement or activity of the elbow joint was prohibited. The recovery status of the osteochondritis dissociation in both groups was followed up at 1, 3, 6, and 12 months postoperatively.
  2. Phase 2: Ten more patients were enrolled to compare the clinical differences between one and two shock wave treatments. Patients were randomly assigned to an experimental group and a control group. Under general anesthesia, the location of osteochondritis dissociation in the humeral capitula was first located using fluoroscopy. Then, extracorporeal shock wave therapy (Storz) was applied to the osteochondritis dissociation in the humeral capitula, with the energy selected randomly at 3000 impulses at 28kV. Postoperatively, the elbow joint was protected with a brace, and any weight-bearing movement or activity of the elbow joint was prohibited. The experimental group received a second shock wave therapy 3 months after the first treatment, with the elbow joint protected with a brace, and any weight-bearing movement or activity of the elbow joint was prohibited. The recovery status of osteochondritis dissociation in both groups was followed up at 1, 3, 6, and 12 months postoperatively.
02

Conditions studied

  • Elbow Osteochondritis Dissecans

Keywords

  • OCD
  • Osteochondritis dissecans
  • ESWT
  • Extracorporeal Shock Wave Therapy
  • Elbow OCD
03

In context

Osteochondritis Dissecans

28 studies on the registry are indexed under Osteochondritis Dissecans; 7 are open to participants now.

This study's enrollment of 9 is below the median of 50 across 15 interventional studies indexed under Osteochondritis Dissecans.

Browse Osteochondritis Dissecans studies →

Lead sponsor

Chang Gung Memorial Hospital is the lead sponsor of 1,091 studies on the registry; 237 are open to participants now.

Browse Chang Gung Memorial Hospital studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
15 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Confirmed by magnetic resonance imaging (MRI) or X-ray of osteochondritis of the lateral epicondyle of the elbow.
  2. Athletes aged 15-18 years with partial or complete fusion of the growth plate.
  3. Ineffective conservative treatment after 3 months.

Exclusion criteria

Exclusion Criteria:

  1. Osteochondritis of the lateral epicondyle has entered the fragmentation stage.
  2. Elbow range of motion is limited to more than 20 degrees.
  3. The growth plate remains open.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
9 participants (actual)

Study arms

  • Placebo comparator
    no-energy shock wave

    Only the sound of shock waves, no energy

    Device: Extracorporeal Shock Wave Therapy(no-energy)

  • Experimental
    ESWT

    Extracorporeal shock wave therapy (Storz) was used on osteochondritis dissociated at the humeral capitula, 3000 impulses at 28kV.

    Device: Extracorporeal Shock Wave Therapy

Interventions

  • DeviceExtracorporeal Shock Wave Therapy

    Extracorporeal shock wave therapy (Storz) was used on osteochondritis dissociated at the humeral capitula, 3000 impulses at 28kV.

  • DeviceExtracorporeal Shock Wave Therapy(no-energy)

    Only the sound of shock waves, no energy.

06

What researchers measure

Primary outcomes

  1. The Visual Analogue Scale (VAS)

    The Visual Analogue Scale (VAS) is a tool commonly used to quantitatively assess the intensity of pain in patients. The two ends are labeled: • Left end (0 points): Represents "no pain at all". • Right end (10 points or 100 millimeters): Represents "the most intense pain imaginable".

    Time frame: Baseline and 1、 3、 6、 12、 18 months.

  2. Mayo Elbow Performance Score( MEPS)

    The Mayo Elbow Performance Score (MEPS) is a professional assessment tool widely used clinically to evaluate functional recovery after elbow fractures, arthritis, total joint replacement, or surgery. The scale has a total score of 100 points, with higher scores indicating better elbow function. The scale mainly includes four assessment dimensions: Pain (maximum 45 points), Range of Motion (ROM) (maximum 20 points), Stability (maximum 10 points), and Daily Function (maximum 25 points).

    Time frame: Baseline and 1、 3、 6、 12、 18 months

  3. Magnetic Resonance Imaging (MRI)

    Magnetic resonance imaging (MRI) is a medical examination technique that uses a strong magnetic field and radio waves to induce resonance in hydrogen atoms within the body without ionizing radiation, and then reconstructs high-resolution 3D cross-sectional images using a computer. MRI images are used to perform Nelson classification to assess the degree of damage and recovery stability of articular cartilage and subchondral bone in osteochondritis dissecans (OCD).

    Time frame: Baseline and 12 months

  4. Elbow ROM (Elbow Range of Motion)(flexion)

    Elbow ROM refers to the maximum angle and range of motion of the elbow joint under normal conditions in different directions. Flexion: The movement of bending the elbow and bringing the palm closer to the shoulder. The normal angle is approximately 0° to 140°\~150°.

    Time frame: Baseline and 1、 3、 6、 12、 18 months.

  5. Elbow Range of Motion(Elbow ROM) (extension)

    Elbow ROM refers to the maximum angle and range of motion of the elbow joint under normal conditions in different directions. Extension: The movement of straightening the elbow. The normal angle is 0° (some people may naturally have a slight hyperextension of 5°\~10°).

    Time frame: Baseline and 1、 3、 6、 12、 18 months.

07

Study locations

1 site
  • Kaohsiung Chang Gung Memorial Hospital
    Kaohsiung City, 833401, Taiwan
08

References and documents

Individual participant data

Plan to share: No — Patient Personal Information and Regulatory Restrictions

No publications or documents are linked to this record.

09

Updates

1 registry update since Sep 25, 2026
Registered
First appeared on the registry. No changes since
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07884578
Lead sponsor
Chang Gung Memorial Hospital
Responsible party
Sponsor
First posted
Oct 20, 2026
Start date
Feb 12, 2020
Primary completion
Jul 31, 2022
Completion
Jul 31, 2022
Last update
Oct 21, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Osteochondritis Dissecans →

Other studies from this sponsor

Chang Gung Memorial Hospital →

Start the discussion